{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005224","form_type":"8-K","ticker":null,"cik":"0001532346","company_name":"Atreca, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.221334+00:00","generated_at":"2026-06-11T17:22:43.559098+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atreca suspends lead candidate ATRC-101, cuts 40% of staff; Q2 net loss $19.2M","bullets":["Suspension of ATRC-101 development and ~40% workforce reduction; estimated restructuring costs of $1.6M in Q3 2023.","Q2 2023 net loss of $19.2M ($0.49 per share); cash and investments totaled $38.5M as of June 30, 2023.","R&D expenses $12.9M and G&A expenses $6.8M for Q2 2023, including stock-based compensation.","Focus shifts to preclinical ADC APN-497444; expects to nominate clinical candidate in 2023 and IND in late 2024/early 2025.","Cash runway expected to fund operations through early 2024; company evaluating additional cost-saving initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005224","json":"https://secwatch.observer/filing/0001171843-23-005224.json","markdown":"https://secwatch.observer/filing/0001171843-23-005224.md","text":"https://secwatch.observer/filing/0001171843-23-005224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1532346/000117184323005224/0001171843-23-005224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1532346/000117184323005224/f8k_081023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:22:43.559098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"674b94fb7195b7d63ac56aac4738e9fa93f5cbc8","claim":"Atreca, Inc. announced a restructuring with charges of approximately $1.6 million affecting operations (approximately 40% of its current employees).","evidence_excerpt":"On August 10, 2023, the Company implemented and announced a corporate reorganization of its operations. As part of the reorganization, the Company is undertaking cost-saving initiatives, including a workforce reduction of approximately 40% of its current employees and the suspension of the development of ATRC-101, its former lead product candidate. The total cost related to the workforce reduction is estimated to be approximately $1.6 million, all of which is cash-based expenditures related primarily to severance payments.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1532346/000117184323005224/0001171843-23-005224-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.6 million"},{"label":"Affected area","value":"operations"},{"label":"Headcount","value":"approximately 40% of its current employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}